NYXH Stock Overview
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nyxoah S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.23 |
| 52 Week High | €20.00 |
| 52 Week Low | €4.00 |
| Beta | 0.55 |
| 1 Month Change | -24.15% |
| 3 Month Change | -34.73% |
| 1 Year Change | 3.52% |
| 3 Year Change | -64.45% |
| 5 Year Change | n/a |
| Change since IPO | -65.71% |
Recent News & Updates
Shareholder Returns
| NYXH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -15.7% | 0.5% | 1.6% |
| 1Y | 3.5% | -0.4% | 26.2% |
Return vs Industry: NYXH exceeded the US Medical Equipment industry which returned -0.1% over the past year.
Return vs Market: NYXH underperformed the US Market which returned 26% over the past year.
Price Volatility
| NYXH volatility | |
|---|---|
| NYXH Average Weekly Movement | 15.7% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NYXH's share price has been volatile over the past 3 months.
Volatility Over Time: NYXH's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 147 | Olivier Taelman | www.nyxoah.com |
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. Fundamentals Summary
| NYXH fundamental statistics | |
|---|---|
| Market cap | US$251.54m |
| Earnings (TTM) | -US$46.55m |
| Revenue (TTM) | US$4.68m |
53.7x
P/S Ratio-5.4x
P/E RatioIs NYXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYXH income statement (TTM) | |
|---|---|
| Revenue | €4.35m |
| Cost of Revenue | €1.66m |
| Gross Profit | €2.69m |
| Other Expenses | €45.90m |
| Earnings | -€43.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 61.91% |
| Net Profit Margin | -993.84% |
| Debt/Equity Ratio | 8.9% |
How did NYXH perform over the long term?
See historical performance and comparison